To order this 320+ page report,which features 110+ figures and 140+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
Key Market Insights
§ Presently, over 150 neoantigen targeted therapies are beingevaluated for advanced cancer indications and are designed for delivery viadifferent routes of administration
§ Several molecules are in early stages of clinicaldevelopment; based on delivery strategies, variety of vaccines andimmunotherapies have been established for targeting personalized and sharedantigens
§ Over the years, more than 6,000 patents related toneoantigens and affiliated therapies have been granted / filed; this isindicative of the heightened pace of research in this field
§ Both industry and academic players are contributing to theinnovation, which is evident across published scientific literature focused onmultiple targeted therapies for a myriad of cancer indications
§ Several investors, having realized the untapped opportunitywithin this emerging segment of cancer immunotherapy, have invested over USD 7billion across 150 instances in the period between 2014 and 2019
§ The increasing traction in this field is also reflected inthe partnership activity; deals inked in the recent past focused on a diverserange of therapies, involving both international and indigenous stakeholders
§ The market will receive the required impetus after approvalof the first neoantigen targeted therapy; the future growth is likely to bedriven by the successful clinical outcomes of the late-stage molecules
§ In fact, opinions from industry experts confirm the vastpotential of this segment of cancer immunotherapy, capable of targetingpersonalized / off-the-shelf tumour antigens with multiple types of vaccinesand therapies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
Contact Details:
GauravChaudhary
+1 (415) 800 3415
